Sight Sciences (SGHT) Set to Post Earnings on Wednesday

Sight Sciences (NASDAQ:SGHT) is expected to release its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Sight Sciences to post earnings of ($0.12) per share and revenue of $23.51 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Wednesday, August 5th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.10. The firm had revenue of $23.39 million during the quarter, compared to the consensus estimate of $21.72 million. Sight Sciences had a negative return on equity of 43.39% and a negative net margin of 35.69%. On average, analysts expect Sight Sciences to post ($0.48) EPS for the current fiscal year and ($0.37) EPS for the next fiscal year.

Sight Sciences Stock Performance

SGHT opened at $9.32 on Monday. The firm has a market capitalization of $513.44 million, a P/E ratio of -16.64 and a beta of 2.44. The stock’s 50 day moving average price is $8.59 and its two-hundred day moving average price is $6.01. The company has a quick ratio of 4.67, a current ratio of 4.95 and a debt-to-equity ratio of 0.58. Sight Sciences has a 12-month low of $3.38 and a 12-month high of $9.71.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on SGHT shares. Wall Street Zen raised Sight Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sight Sciences in a research note on Friday, August 7th. Citigroup increased their price target on shares of Sight Sciences from $8.00 to $10.00 and gave the company a “neutral” rating in a report on Monday, October 5th. UBS Group increased their price target on shares of Sight Sciences from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, HC Wainwright began coverage on shares of Sight Sciences in a research report on Thursday, October 15th. They issued a “buy” rating and a $14.00 price target on the stock. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Sight Sciences has an average rating of “Moderate Buy” and a consensus price target of $9.25.

Insider Transactions at Sight Sciences

In related news, CTO David Badawi sold 7,797 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total value of $70,562.85. Following the completion of the transaction, the chief technology officer directly owned 1,975,075 shares in the company, valued at approximately $17,874,428.75. This represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Paul Badawi sold 29,653 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total value of $268,359.65. Following the completion of the transaction, the chief executive officer directly owned 6,092,819 shares of the company’s stock, valued at approximately $55,140,011.95. This trade represents a 0.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 47,646 shares of company stock worth $429,157 over the last 90 days. Insiders own 30.40% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.